1-溴-4-(二氟甲基)苯 | 51776-71-7

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 烃类卤化物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-溴-4-(二氟甲基)苯
• 中文别名: 4-溴-α,α-二氟甲苯
• 英文名称: 1-bromo-4-(difluoromethyl)benzene
• CAS: 51776-71-7
• 化学式: C₇H₅BrF₂
• mdl: MFCD06657964
• 分子量: 207.018
• InChiKey: HUSPSWKWFREKSS-UHFFFAOYSA-N

物化性质

• 沸点：
  100℃/53mm
• 密度：
  1.604 g/mL at 25 °C
• 闪点：
  87°C

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S26,S37,S60
• 危险类别码：
  R36/37/38
• WGK Germany：
  2
• 海关编码：
  2903999090
• 包装等级：
  III
• 危险类别：
  3
• 危险性防范说明：
  P210,P240,P242,P243,P261,P264,P270,P271,P280,P303+P361+P353,P304+P340,P305+P351+P338,P312,P330,P363,P370+P378,P403+P233,P501
• 危险品运输编号：
  1993
• 危险性描述：
  H225,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Bromo-4-(difluoromethyl)benzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
H227: Combustible liquid
Keep away from heat/sparks/open flames/hot surfaces. No smoking
P210:
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Bromo-4-(difluoromethyl)benzene
CAS number: 51776-71-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H5BrF2
Molecular weight: 207.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  对溴甲苯	para-bromotoluene	106-38-7	C7H7Br	171.037

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	1-Bromo-4-[18F](trifluoromethyl)benzene	1456616-01-5	C7H4BrF3	224.01
  对溴三氟甲苯	p-trifluoromethylphenyl bromide	402-43-7	C7H4BrF3	225.008
  4-(二氟溴甲基)溴苯	1-bromo-4-(bromodifluoromethyl)benzene	2358-32-9	C7H4Br2F2	285.914

反应信息

• 作为反应物：
  描述：

  1-溴-4-(二氟甲基)苯 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氯化碳 为溶剂， 以80 %的产率得到4-(二氟溴甲基)溴苯
  参考文献：
  名称：

  A General Organophotoredox Strategy to Difluoroalkyl Bicycloalkane (CF2‐BCA) Hybrid Bioisosteres**

  摘要：

  摘要我们在此报告一种合成二氟烷基双环烷烃（CF2-BCAs）的通用方法，作为芳基酮和醚的结构代用品。化学反应由二氢苯并吖啶光催化剂驱动，该催化剂可参与催化电子-供体受体（EDA）复合物，或直接还原含氟底物。这两种趋同的流形导致 R-CF2 自由基的产生，并与 [1.1.1]- 或 [3.1.1.]- 丙烷发生反应。该方法非常通用，可扩展到复杂的生物活性分子（30 个实例，收率高达 87%）。我们通过单晶 X 射线研究了 CF2-BCP 混合生物异质体的结构特征。最后，我们合成了一种白三烯 A4 水解酶抑制剂的 CF2-BCP 类似物，取代了原来的芳基醚基团。硅学对接研究表明，这种新的类似物在酶袋内保持了相同的排列方式，从而剖析了 CF2-BCA 混合生物异构体在药物化学领域的应用。

  DOI：

  10.1002/anie.202303585
• 作为产物：
  描述：

  对溴苯甲醛 在 potassium fluoride 、 甲酸 、 四甲基氟化铵 、 N,N-硫酰二咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以87%的产率得到1-溴-4-(二氟甲基)苯
  参考文献：
  名称：

  硫酰氟和四甲基氟化铵在室温下对苯甲醛和α-酮酸酯进行脱氧氟化

  摘要：

  描述了使用硫酰氟和Me 4 NF在室温下对苯甲醛和α-酮酸酯进行脱氧氟化的方法。证明了大范围的芳基和杂芳基底物，并且该方法与许多底物的其他常见脱氧氟化方法相比具有优势。

  DOI：

  10.1021/acs.orglett.9b00054
• 作为试剂：
  描述：

  1-bromo-4-(difluoro(methyloxy)methyl)benzene 、 3-氟异喹啉-6-基硼酸 、 tert-butyl (5-bromo-1,3-thiazol-2-yl)((2S)-2-((tert-butoxycarbonyl)amino)-3-(4-(difluoro(methoxy)methyl)phenyl)propyl)carbamate 、 在 1-溴-4-(二氟甲基)苯 作用下， 以to provide methyl 4-((2S)-2-((tert-butoxycarbonyl)amino)-3-((tert-butoxycarbonyl)(5-(3-fluoro-6-isoquinolinyl)-1,3-thiazol-2-yl)amino)propyl)benzoate as the cross-coupled product的产率得到methyl 4-((2S)-2-((tert-butoxycarbonyl)amino)-3-((tert-butoxycarbonyl)(5-(3-fluoro-6-isoquinolinyl)-1,3-thiazol-2-yl)amino)propyl)benzoate
  参考文献：
  名称：

  FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE

  摘要：

  本发明涉及一种式I的噻唑化合物及其组合物，其在治疗由蛋白激酶B（PKB）介导的疾病方面具有用途，其中变量具有本文所提供的定义。本发明还涉及在治疗与异常细胞生长、癌症、炎症和代谢紊乱有关的疾病状态中使用此类噻唑化合物和其组合物的治疗用途。

  公开号：

  US20110263647A1

文献信息

• [EN] A NEW METHOD OF 18F LABELLING AND INTERMEDIATE SALTS<br/>[FR] NOUVEAU PROCÉDÉ D'ÉTIQUETAGE DE 18F ET DE SELS INTERMÉDIAIRES
  申请人：NAT UNIV SINGAPORE

  公开号：WO2021126080A1

  公开（公告）日：2021-06-24

  Disclosed herein is a salt of formula I: where R1, X, n, R, R1, Y, m, p, q, Z and o are as defined herein. Also disclosed herein are methods of using said salts in chemical synthesis, such as to prepare compounds isotopically enriched in 18F for use in PET imaging, as well as methods to make the compounds of formula I.

  披露的是公式I的盐：其中R1、X、n、R、R1、Y、m、p、q、Z和o如本文所述定义。还披露了使用所述盐进行化学合成的方法，例如用于制备在正电子发射断层扫描（PET）成像中使用的18F同位素富集化合物，以及制造公式I化合物的方法。
• 2-PYRIDONE COMPOUNDS
  申请人：KAWAGUCHI Takanori

  公开号：US20110237791A1

  公开（公告）日：2011-09-29

  A 2-pyridone compound represented by the formula [1]: wherein in the formula [1], the ring represented by A represents a benzene ring or a pyridine ring, X represents any of the structures represented by the formulas [3] shown below: V represents a single bond or a lower alkylene group, and W represents a single bond, an ether bond or a lower alkylene group (wherein the lower alkylene group may contain an ether bond)}, a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is a compound that has an excellent GK activating effect and is useful as a pharmaceutical.

  化学式为[1]所代表的2-吡啶酮化合物： 其中在化学式[1]中， 由A代表苯环或吡啶环表示的环， X代表下面所示的化学式[3]所代表的任意结构： V代表单键或较低的烷基链，以及 W代表单键、醚键或较低的烷基链（其中较低的烷基链可能含有醚键）}， 该化合物的异构体或立体异构体，其药学上可接受的盐，或其溶剂化合物是一种具有出色的GK激活效果并且可用作药物的化合物。
• AMINOAZOLE DERIVATIVE
  申请人：Teijin Pharma Limited

  公开号：US20190031628A1

  公开（公告）日：2019-01-31

  A compound, represented by the following formula or a medically acceptable salt thereof, having an effect of regulating the activity of an androgen receptor. In the formula, X represents S, O; Z represents (R a ) n -A- (CR 13 R 14 ) 0-1 —(CR 11 R 12 ) 0-1 ; A represents aryl, heteroaryl; R 1 represents alkyl, cycloalkyl, alkenyl, alkynyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl; R 2 represents hydrogen, halogen, alkyl, cycloalkyl, phenyl; R3 represents hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkenyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl, acyl, cycloalkylcarbonyl, benzoyl, spiroalkyl, adamantyl, silyl, R 31 R 32 NCO—; R 4 and R 5 represent hydrogen, halogen, alkyl, phenyl, and cycloalkyl.

  一种化合物，由以下公式或其医学上可接受的盐表示，具有调节雄激素受体活性的作用。在公式中，X代表S，O；Z代表（R a ）n-A-（CR 13 R 14 ）0-1—（CR 11 R 12 ）0-1；A代表芳基，杂环芳基；R1代表烷基，环烷基，烯基，炔基，烷氧基烷基，芳基，芳基烷基，杂环，杂环烷基；R2代表氢，卤素，烷基，环烷基，苯基；R3代表氢，卤素，烷基，环烷基，烷氧基烷基，烯基，炔基，环烯烯基，芳基，芳基烷基，杂环，杂环烷基，酰基，环烷基羰基，苯甲酰基，螺环烷基，金刚烷基，硅基，R31R32NCO—；R4和R5代表氢，卤素，烷基，苯基和环烷基。
• Nickel-Catalyzed Aromatic Cross-Coupling Difluoromethylation of Grignard Reagents with Difluoroiodomethane
  作者：Hirotaka Motohashi、Koichi Mikami

  DOI：10.1021/acs.orglett.8b02264

  日期：2018.9.7

  The nickel-catalyzed cross-coupling difluoromethylation of the Grignard reagents with difluoroiodomethane is shown to provide the corresponding aromatic difluoromethyl products in excellent to moderate yields. The difluoromethylation proceeds smoothly within 1 h at room temperature with 1.5 equiv of the Grignard reagents in the presence of Ni(cod)2/TMEDA (2.5–0.5 mol %). Mechanistic studies clarify

  格氏试剂与二氟碘甲烷的镍催化交叉偶联二氟甲基化可提供优异至中等收率的相应芳族二氟甲基产物。在存在Ni（cod）2 / TMEDA（2.5-0.5 mol％）的情况下，在室温下1个小时内，用1.5当量的格氏试剂，二氟甲基化反应平稳进行。机理研究表明，将Ni（0）催化剂氧化添加到二氟碘甲烷中可提供TMEDA-Ni（II）（CF 2 H）I络合物。该中间体被转化为TMEDA–Ni（II）（CF 2H）Ph通过与PhMgBr进行重金属化而获得。进行还原消除，得到芳香族交叉偶联的二氟甲基化产物，以及TMEDA-Ni（0）催化剂的再生。镍催化反应的电子顺磁共振（EPR）和自由基钟分析没有提供在g = 2左右的EPR活性Ni（I）和Ni（III）物种，仅提供了痕量的环化产物。
• EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US20170145026A1

  公开（公告）日：2017-05-25

  The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R 1 , R 2 , R 3a , R 3b , R 4a , R 4b and R 5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

  本发明提供了根据式I合成的化合物、药用可接受的配方和用途，或其立体异构体、互变异构体或药用可接受的盐。对于式I化合物X、Y、R1、R2、R3a、R3b、R4a、R4b和R5如规范中所定义。这些创新的式I化合物是eIF4A的抑制剂，在许多治疗应用中发挥作用，包括但不限于治疗炎症和各种癌症。